Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2008 Nov 4;27(1):59.
doi: 10.1186/1756-9966-27-59.

Prolonged response to first-line erlotinib for advanced lung adenocarcinoma

Michael Copeman  1
Affiliations
Case Reports

Prolonged response to first-line erlotinib for advanced lung adenocarcinoma

Michael Copeman. J Exp Clin Cancer Res. .

Abstract

A 58-year-old, non-smoking female of Philippine origin presented with painful thoracic and neck nodal relapse of lung adenocarcinoma almost 5 years after left pneumonectomy for stage II non-small-cell lung cancer. She refused conventional chemotherapy or radiation because of toxicity concerns, but agreed to oral erlotinib 150 mg/day. Within weeks, her pain was well controlled, with softening of palpable neck nodes. Repeat scans after 7 months on erlotinib showed partial response of thoracic disease and nodal metastases. This response was maintained for 11 months on erlotinib, with symptomatic progression at the original sites of relapse by 15 months. Erlotinib was well tolerated, with grade 2-3 rash, and grade 1 dry cough and diarrhoea being the only significant toxicities. Importantly, the patient was able to maintain daily activities throughout erlotinib therapy.

PubMed Disclaimer

References

    1. Wakelee H, Belani CP. Optimizing first-line treatment options for patients with advanced NSCLC. Oncologist. 2005;10(Suppl 3):1–10. doi: 10.1634/theoncologist.10-90003-1. - DOI - PubMed
    1. Pujol J-L, Barlesi F, Daures J-P. Should chemotherapy combinations for advanced non-small cell lung cancer be platinum-based? A meta-analysis of phase III randomized trials. Lung Cancer. 2006;51:335–345. doi: 10.1016/j.lungcan.2005.11.001. - DOI - PubMed
    1. Shepherd FA, Rodrigues PJ, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, Campos D, Maoleekoonpiroj S, Smylie M, Martins R, van Kooten M, Dediu M, Findlay B, Tu D, Johnston D, Bezjak A, Clark G, Santabárbara P, Seymour L, National Cancer Institute of Canada Clinical Trials Group Erlotinib in previously treated non-small-cell lung cancer. N Eng J Med. 2005;353:123–132. doi: 10.1056/NEJMoa050753. - DOI - PubMed
    1. Bezjak A, Tu D, Seymour L, Clark G, Trajkovic A, Zukin M, Ayoub J, Lago S, de Albuquerque Ribeiro R, Gerogianni A, Cyjon A, Noble J, Laberge F, Chan RT, Fenton D, von Pawel J, Reck M, Shepherd FA, National Cancer Institute of Canada Clinical Trials Group Study BR.21 Symptom improvement in lung cancer in patients treated with erlotinib: quality of life analysis of the National Cancer Institute of Canada Clinical Trials Group study BR.21. J Clin Oncol. 2006;24:3831–3837. doi: 10.1200/JCO.2006.05.8073. - DOI - PubMed
    1. Ramalingam S, Sandler AB. Salvage therapy for advanced non-small cell lung cancer: factors influencing treatment selection. Oncologist. 2006;11:655–665. doi: 10.1634/theoncologist.11-6-655. - DOI - PubMed

Publication types

MeSH terms